{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:14:47Z","timestamp":1790835287555,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100025606","name":"Chambers Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["chestpulmonary.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST Pulmonary"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.chpulm.2024.100080","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T07:08:31Z","timestamp":1719644911000},"page":"100080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-2632","authenticated-orcid":false,"given":"Bradley H.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-0585","authenticated-orcid":false,"given":"Kevin J.","family":"Psoter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Sabadosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgene E.","family":"Hergenroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6372-6545","authenticated-orcid":false,"given":"Lisa L.","family":"Bendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nell Meosky","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9160-8865","authenticated-orcid":false,"given":"Connie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"Clement L.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-0561","authenticated-orcid":false,"given":"Cynthia D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.chpulm.2024.100080_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100080_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.12.009","article-title":"Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes","volume":"12","author":"Sawicki","year":"2013","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.chpulm.2024.100080_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ppul.22546","article-title":"Managing treatment complexity in cystic fibrosis: challenges and opportunities","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.chpulm.2024.100080_bib4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"17","key":"10.1016\/j.chpulm.2024.100080_bib5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100080_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chpulm.2024.100080_bib7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chpulm.2024.100080_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"23","key":"10.1016\/j.chpulm.2024.100080_bib9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chpulm.2024.100080_bib10","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2213-2600(13)70199-1","article-title":"Integrating real-life studies in the global therapeutic research framework","volume":"1","author":"Roche","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"suppl 2","key":"10.1016\/j.chpulm.2024.100080_bib11","doi-asserted-by":"crossref","first-page":"s92","DOI":"10.1513\/AnnalsATS.201308-276RM","article-title":"Complementing the randomized controlled trial evidence base. Evolution not revolution","volume":"11","author":"Price","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100080_bib12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jcf.2020.03.020","article-title":"Real-world evidence in cystic fibrosis modulator development: establishing a path forward","volume":"19","author":"Magaret","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"suppl 2","key":"10.1016\/j.chpulm.2024.100080_bib13","doi-asserted-by":"crossref","first-page":"s112","DOI":"10.1513\/AnnalsATS.201309-327RM","article-title":"Integrating patients into meaningful real-world research","volume":"11","author":"Bartlett","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"16","key":"10.1016\/j.chpulm.2024.100080_bib14","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs\u00a0real-world evidence: how can both inform decision-making?","volume":"329","author":"Sheldrick","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.chpulm.2024.100080_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.chpulm.2024.100080_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.chpulm.2024.100080_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["CHEST Pulmonary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T06:07:06Z","timestamp":1735279626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949789224000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2949789224000461"],"URL":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100080","relation":{},"ISSN":["2949-7892"],"issn-type":[{"value":"2949-7892","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST Pulmonary","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100080"}}